From Wikipedia, the free encyclopedia - View original article
|Classification and external resources|
|Classification and external resources|
Castleman's disease (giant or angiofollicular lymph node hyperplasia, lymphoid hamartoma, angiofollicular lymph node hyperplasia) is an uncommon lymphoproliferative disorder that may be localized to a single lymph node (unicentric) or occur systemically (multicentric). It must be distinguished from reactive lymph node hyperplasia and malignancies. It is a very rare disorder characterized by non-cancerous growths (tumors) that may develop in the lymph node tissue at a single site or throughout the body. It involves hyperproliferation of certain B cells that often produce cytokines. While not officially considered a cancer, the overgrowth of lymphocytes with this disease is similar to lymphoma.
There are several variants of Castleman's disease.
In most of the cases, Castleman's disease is likely due to hypersecretion of the cytokine IL-6, but some patients may have normal IL-6 levels and present with non-iron-deficient microcytic anemia.
Unicentric Castleman's disease involves tissue growths at only a single site. It usually has few or no symptoms other than those directly associated with the enlargement of the lymph node. In 90% or more, removal of the enlarged node is curative, with no further complications. However, in 2011, Weng et al. described a patient with unicentric Castleman's disease, hyaline vascular type, presenting with severe chronic non-iron-deficient anemia. He suggested that in patients with normal IL-6 level may present with non-iron deficient type and may resolve after effective treatment of Castleman's disease.
Multicentric Castleman's disease (MCD) involves growths at multiple sites. About 50% is caused by KSHV, also called HHV-8, a gammaherpesvirus that is also the cause of Kaposi's sarcoma and primary effusion lymphoma, while the remainder of MCD are of unknown cause. The form of MCD most closely associated with KSHV is the plasmacytic form of Castleman's disease while another pathologic form, the hyaline-vascular form, is generally negative for this virus.
The most common 'B Symptoms' of MCD are high fevers, anemia, weight loss, loss of appetite, and low white blood cell counts, which may to be due to the overproduction of interleukin 6. Symptomatically, therefore, MCD can be difficult to diagnose and even in the case of a lymph-node biopsy a conclusive diagnosis remains problematic.
There is no standard therapy for multicentric Castleman's disease. Treatment modalities include antiviral drugs such as ganciclovir for human herpesvirus type 8 (HHV-8), chemotherapy, corticosteroids, immunomodulators, monoclonal antibodies against IL-6, and thalidomide.
It is important to distinguish AIDS-related multicentric Castleman’s disease from other forms of multicentric Castleman’s disease. Treatment for the former can be focused upon the same protocols used for treating the underlying AIDS.
Prior to 1996 MCD carried a poor prognosis of about 2 years, due to autoimmune hemolytic anemia and non-Hodgkin's lymphoma which may arise as a result of proliferation of infected cells. The timing of diagnosis, with particular attention to the difficulty of determining the cause of B symptoms without a CT scan and lymph node biopsy, may impact significantly on the prognosis and risk of death. Left untreated, MCD usually gets worse and becomes increasingly difficult and unresponsive to current treatment regimens.
Recent work with HIV-positive patients with KSHV-related MCD suggests that treatment with the antiherpesvirus drug ganciclovir or the antiCD20 B cell monoclonal antibody, rituximab, may markedly improve outcome. These drugs target and kill B cells via the B cell specific CD20 marker. Since B cells are required for the production of antibodies, the body's immune response is weakened whilst on treatment and the risk of further viral or bacterial infection is increased. Due to the uncommon nature of the condition there are not many large scale research studies from which standardized approaches to therapy may be drawn, and the extant case studies of individuals or small cohorts should be read with caution. As with many diseases, the patient's age, physical state and previous medical history with respect to infections may impact the disease progression and outcome.
Siltuximab, a monoclonal antibody that binds interleukin-6, preventing it from binding to the IL-6 receptor, was submitted to the U.S. Food and Drug Administration for approval in October, 2013.  Preliminary data suggest that treatment siltuximab may achieve tumour and symptomatic response in 34% of patients with MCD.
Other treatments for multicentric castleman disease include the following: